secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2021-08-16T23:59:59+00:00
Accession:  0001104659-21-106315
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx Q2 2021 net loss $4.0M ($0.57/diluted share); IPO raised $17.25M gross
----------------------------------------------------------------------------

- Net loss of $4.0M for Q2 2021 vs $0.9M loss in Q2 2020; R&D expenses down to $0.1M from $0.4M.
- Cash balance $17.1M as of June 30, 2021, following June IPO gross proceeds of $17.25M including overallotment.
- Health Holland awarded ~$500K grant to Leiden University to study DNA pol IIIC inhibitors in collaboration with Acurx.
- Filed provisional patent for ibezapolstat to treat C. difficile infection with reduced recurrence and improved microbiome health.
- SG&A expenses rose to $3.9M in Q2 2021 from $0.5M in Q2 2020, driven by stock-based compensation and professional fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465921106315/0001104659-21-106315-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465921106315/tm2125031d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-106315

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer